GlassScriptPhysician profile
Daniel S Fuleihan
NPI 1245226919
$4,664.35
in general payments reported to CMS, 2019-2025
30 companies · $398 in 2025
The $398 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $251 · 2021: $28.49 · 2022: $150 · 2023: $1,191 · 2024: $1,191 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $855.62 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $611.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.10 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $360.18 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $277.29 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $273.64 | 2022-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $223.71 | 2019-2023 | Watchman Flx, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $180.12 | 2019-2023 | Evkeeza |
| Gilead Sciences, INC. | $141.50 | 2019 | |
| Pfizer INC. | $115.16 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.92 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $108.50 | 2022-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $90.57 | 2019-2025 | Navitor, Cardiomems |
| Lexicon Pharmaceuticals, INC. | $86.41 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $85.74 | 2022-2025 | Farxiga, Brilinta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $82.79 | 2023-2025 | Impella |
| Biotronik INC. | $79.88 | 2019-2020 | |
| Vifor Pharma, INC. | $62.24 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.59 | 2025 | Caplyta |
| Amarin Pharma, INC. | $49.48 | 2019 | |
| Scpharmaceuticals INC. | $49.18 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $48.89 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $41.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.43 | 2025 | |
| Novo Nordisk INC | $36.88 | 2019-2024 | Wegovy |
| Esperion Therapeutics, INC. | $32.62 | 2023-2024 | Nexletol |
| Medtronic, INC. | $18.54 | 2023 | Linq II |
| Kiniksa Pharmaceuticals, LTD. | $18.31 | 2023 | Arcalyst |
| Akcea Therapeutics, INC. | $15.50 | 2020 | |
| Glaxosmithkline, LLC. | $14.35 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fuleihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.